BTD
Biotinidase
Also known as: BTD_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P43251
- Gene
- BTD
- Ensembl
- ENSG00000169814
- Chromosome
- 3
- Canonical length
- 543 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene functions to recycle protein-bound biotin by cleaving biocytin (biotin-epsilon-lysine), a normal product of carboxylase degradation, resulting in regeneration of free biotin. The encoded protein has also been shown to have biotinyl transferase activity. Mutations in this gene are associated with biotinidase deficiency. Multiple transcript variants encoding different isoforms have been described. [provided by RefSeq, Aug 2013]
Canonical amino-acid sequenceUniProt
543 residues, UniProt reviewed canonical sequence.
>P43251|BTD
1 MAHAHIQGGR RAKSRFVVCI MSGARSKLAL FLCGCYVVAL GAHTGEESVA DHHEAEYYVA
61 AVYEHPSILS LNPLALISRQ EALELMNQNL DIYEQQVMTA AQKDVQIIVF PEDGIHGFNF
121 TRTSIYPFLD FMPSPQVVRW NPCLEPHRFN DTEVLQRLSC MAIRGDMFLV ANLGTKEPCH
181 SSDPRCPKDG RYQFNTNVVF SNNGTLVDRY RKHNLYFEAA FDVPLKVDLI TFDTPFAGRF
241 GIFTCFDILF FDPAIRVLRD YKVKHVVYPT AWMNQLPLLA AIEIQKAFAV AFGINVLAAN
301 VHHPVLGMTG SGIHTPLESF WYHDMENPKS HLIIAQVAKN PVGLIGAENA TGETDPSHSK
361 FLKILSGDPY CEKDAQEVHC DEATKWNVNA PPTFHSEMMY DNFTLVPVWG KEGYLHVCSN
421 GLCCYLLYER PTLSKELYAL GVFDGLHTVH GTYYIQVCAL VRCGGLGFDT CGQEITEATG
481 IFEFHLWGNF STSYIFPLFL TSGMTLEVPD QLGWENDHYF LRKSRLSSGL VTAALYGRLY
541 ERDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against BTD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 94 nTPM
Expression across tissuesHPA
Tissue
- liver: 94 nTPM
- epididymis: 60 nTPM
- duodenum: 47 nTPM
- pancreas: 44 nTPM
- kidney: 35 nTPM
- retina: 32 nTPM
Single-cell type
- plasma cells: 558 nCPM
- rod photoreceptor cells: 415 nCPM
- epicardial cells: 359 nCPM
- adipocytes: 336 nCPM
- mast cells: 306 nCPM
- thymocytes: 267 nCPM
Immune cell
- basophil: 79 nTPM
- eosinophil: 49 nTPM
- T-reg: 31 nTPM
- plasmacytoid DC: 26 nTPM
- memory CD4 T-cell: 25 nTPM
- gdT-cell: 24 nTPM
Brain region
- cerebellum: 51 nTPM
- white matter: 51 nTPM
- medulla oblongata: 38 nTPM
- basal ganglia: 38 nTPM
- pons: 36 nTPM
- hippocampal formation: 36 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about BTD.
Disease | AllUniProt
Conditions BTD is implicated in, by any mechanism.
- Biotinidase deficiency (BTD deficiency) MIM:253260
Disease | GeneticClinVar
253 pathogenic / likely-pathogenic of 773 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Biotinidase deficiency
- Inborn genetic diseases
- BTD-related disorder
- Intellectual disability
- Colon adenocarcinoma
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.3
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.53
- DepMap mean gene effect
- 0.23
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- biotinidase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads BTD as an antibody target. Whether an autoantibody or antibody against BTD could matter depends on whether native BTD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
BTD is annotated as secreted, so native BTD circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label BTD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...